TapewireFind a company

person · Reporting owner

Loeillot Olivier

Disclosed activity across 1 company

Tapewire entity
21079
SEC CIK
0001995525

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
REPLIGEN CORPRGEN · Entity 486Director · Chief Executive OfficerOctober 05, 2026October 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

REPLIGEN CORP

Report date October 05, 2026 · Filed October 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect45,788 Ending reported balance After 2026-10-05 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2026-10-05 · Sale · Disposed 1,333 · Balance 45,788

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Row 2 · 2026-10-05 · Exercise / conversion · Acquired 4,202 · Balance 49,990

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Row 3 · 2026-10-05 · Sale · Disposed 4,202 · Balance 45,788

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $154.96 · Expires 2033-10-02Direct8,405 Reported balance After 2026-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-10-05 · Exercise / conversion · Disposed 4,202 · Balance 8,405

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

F2: 4,202 shares will vest on October 2, 2027. 4,203 shares will vest on October 2, 2028.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

F2: 4,202 shares will vest on October 2, 2027. 4,203 shares will vest on October 2, 2028.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 05, 2026 Filed Oct 6, 2026 20:18 UTC REPLIGEN CORP RGEN · Entity 486 Exercise / conversionStock Option (Right to Buy) · Derivative 4,202 $0.00 Strike: $154.96 $0.00
Disclosure

SEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · derivative · entry 4

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,405

Underlying: Common Stock · 4,202 shares

Expires 2033-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

F2 · derivative.exercise_date: 4,202 shares will vest on October 2, 2027. 4,203 shares will vest on October 2, 2028.

Read SEC document
October 05, 2026 Filed Oct 6, 2026 20:18 UTC REPLIGEN CORP RGEN · Entity 486 SaleCommon Stock 4,202 $190.00 $798,380.00
Disclosure

SEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 3

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,788

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
October 05, 2026 Filed Oct 6, 2026 20:18 UTC REPLIGEN CORP RGEN · Entity 486 Exercise / conversionCommon Stock 4,202 $154.96 $651,141.92
Disclosure

SEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,990

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
October 05, 2026 Filed Oct 6, 2026 20:18 UTC REPLIGEN CORP RGEN · Entity 486 SaleCommon Stock 1,333 $178.75 $238,273.75
Disclosure

SEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,788

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
October 02, 2026 Filed Oct 5, 2026 20:01 UTC REPLIGEN CORP RGEN · Entity 486 Tax withholdingCommon Stock 1,248 $181.70 $226,761.60
Disclosure

SEC source: 0001628280-26-064889 · wk-form4_1791230479.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,121

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC REPLIGEN CORP RGEN · Entity 486 Exercise / conversionStock Option (Right to Buy) · Derivative 4,542 $0.00 Strike: $155.38 $0.00
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · derivative · entry 6

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,085

Underlying: Common Stock · 4,542 shares

Expires 2035-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

F3 · derivative.exercise_date: 4,542 shares will vest on March 1, 2027, and 4,543 shares will vest on March 1, 2028.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC REPLIGEN CORP RGEN · Entity 486 Exercise / conversionStock Option (Right to Buy) · Derivative 8,404 $0.00 Strike: $154.96 $0.00
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · derivative · entry 5

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,607

Underlying: Common Stock · 8,404 shares

Expires 2033-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

F2 · derivative.exercise_date: 4,202 shares will vest on each of October 2, 2026, and October 2, 2027. 4,203 shares will vest on October 2, 2028.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC REPLIGEN CORP RGEN · Entity 486 SaleCommon Stock 4,542 $190.00 $862,980.00
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 4

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,369

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC REPLIGEN CORP RGEN · Entity 486 Exercise / conversionCommon Stock 4,542 $155.38 $705,735.96
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 3

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC REPLIGEN CORP RGEN · Entity 486 SaleCommon Stock 8,404 $190.00 $1,596,760.00
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,369

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC REPLIGEN CORP RGEN · Entity 486 Exercise / conversionCommon Stock 8,404 $154.96 $1,302,283.84
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,773

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 21, 2026 Filed Sep 22, 2026 20:07 UTC REPLIGEN CORP RGEN · Entity 486 Exercise / conversionStock Option (Right to Buy) · Derivative 5,426 $0.00 Strike: $141.79 $0.00
Disclosure

SEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · derivative · entry 3

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,426

Underlying: Common Stock · 5,426 shares

Expires 2034-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 21, 2026 Filed Sep 22, 2026 20:07 UTC REPLIGEN CORP RGEN · Entity 486 SaleCommon Stock 5,426 $180.00 $976,680.00
Disclosure

SEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · nonDerivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,369

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 21, 2026 Filed Sep 22, 2026 20:07 UTC REPLIGEN CORP RGEN · Entity 486 Exercise / conversionCommon Stock 5,426 $141.79 $769,352.54
Disclosure

SEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 04, 2026 Filed Sep 8, 2026 20:13 UTC REPLIGEN CORP RGEN · Entity 486 SaleCommon Stock 3,035 $165.90 $503,506.50
Disclosure

SEC source: 0001628280-26-060911 · wk-form4_1788898417.xml · nonDerivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,369

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 03, 2026 Filed Sep 8, 2026 20:13 UTC REPLIGEN CORP RGEN · Entity 486 Tax withholdingCommon Stock 2,842 $169.61 $482,031.62
Disclosure

SEC source: 0001628280-26-060911 · wk-form4_1788898417.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,404

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
August 20, 2026 Filed Aug 21, 2026 20:06 UTC REPLIGEN CORP RGEN · Entity 486 Exercise / conversionStock Option (Right to Buy) · Derivative 5,426 $0.00 Strike: $141.79 $0.00
Disclosure

SEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · derivative · entry 3

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,852

Underlying: Common Stock · 5,426 shares

Expires 2034-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

F2 · derivative.exercise_date: 5,426 shares will vest on each of September 3, 2026, and September 3, 2027.

Read SEC document
August 20, 2026 Filed Aug 21, 2026 20:06 UTC REPLIGEN CORP RGEN · Entity 486 SaleCommon Stock 5,426 $180.00 $976,680.00
Disclosure

SEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · nonDerivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,246

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
August 20, 2026 Filed Aug 21, 2026 20:06 UTC REPLIGEN CORP RGEN · Entity 486 Exercise / conversionCommon Stock 5,426 $141.79 $769,352.54
Disclosure

SEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,672

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
April 21, 2026 Filed Apr 22, 2026 17:26 UTC REPLIGEN CORP RGEN · Entity 486 SaleCommon Stock 3,832 $140.00 $536,480.00
Disclosure

SEC source: 0001193125-26-169682 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,246

F1 · price: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on August 19th, 2025.

Read SEC document
March 05, 2026 Filed Mar 23, 2026 15:53 UTC REPLIGEN CORP RGEN · Entity 486 GrantStock Option (Right to Buy) · Derivative 25,890 $0.00 Strike: $141.91 $0.00
Disclosure

SEC source: 0001193125-26-119036 · ownership.xml · derivative · entry 2

Loeillot Olivier · CIK 0001995525 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,890

Underlying: Common Stock · 25,890 shares

Expires 2036-03-05

F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.

Read SEC document
March 05, 2026 Filed Mar 23, 2026 15:53 UTC REPLIGEN CORP RGEN · Entity 486 GrantCommon Stock 24,134 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-119036 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,078

F1 · shares: Mr. Loeillot was awarded 24,134 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
March 02, 2026 Filed Mar 3, 2026 18:39 UTC REPLIGEN CORP RGEN · Entity 486 Tax withholdingCommon Stock 1,610 $124.97 $201,201.70
Disclosure

SEC source: 0001193125-26-087595 · ownership.xml · nonDerivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,944

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 18:39 UTC REPLIGEN CORP RGEN · Entity 486 Tax withholdingCommon Stock 344 $128.73 $44,283.12
Disclosure

SEC source: 0001193125-26-087595 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,554

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
November 25, 2025 Filed Nov 26, 2025 21:30 UTC REPLIGEN CORP RGEN · Entity 486 SaleCommon Stock 7,041 $170.00 $1,196,970.00
Disclosure

SEC source: 0001193125-25-300642 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,898

F1 · price: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 12, 2024.

Read SEC document
October 02, 2025 Filed Oct 6, 2025 14:59 UTC REPLIGEN CORP RGEN · Entity 486 Tax withholdingCommon Stock 1,248 $145.23 $181,247.04
Disclosure

SEC source: 0001193125-25-231365 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,939

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
September 03, 2025 Filed Sep 4, 2025 14:55 UTC REPLIGEN CORP RGEN · Entity 486 Tax withholdingCommon Stock 2,506 $116.18 $291,147.08
Disclosure

SEC source: 0001193125-25-195655 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,187

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
March 03, 2025 Filed Mar 4, 2025 18:18 UTC REPLIGEN CORP RGEN · Entity 486 GrantStock Option (Right to Buy) · Derivative 13,627 $0.00 Strike: $155.38 $0.00
Disclosure

SEC source: 0000950170-25-031547 · ownership.xml · derivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,627

Underlying: Common Stock · 13,627 shares

Expires 2035-03-03

F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on March 3, 2026, March 3, 2027, and March 3, 2028.

Read SEC document
March 03, 2025 Filed Mar 4, 2025 18:18 UTC REPLIGEN CORP RGEN · Entity 486 GrantCommon Stock 14,480 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-031547 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,693

F1 · shares: Mr. Loeillot was awarded 14,480 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
February 27, 2025 Filed Feb 28, 2025 21:30 UTC REPLIGEN CORP RGEN · Entity 486 Tax withholdingCommon Stock 343 $156.54 $53,693.22
Disclosure

SEC source: 0000950170-25-030080 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,213

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of performance stock units.

Read SEC document
November 20, 2024 Filed Nov 21, 2024 18:32 UTC REPLIGEN CORP RGEN · Entity 486 Tax withholdingCommon Stock 861 $123.41 $106,256.01
Disclosure

SEC source: 0000950170-24-129622 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,556

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 00:41 UTC REPLIGEN CORP RGEN · Entity 486 GrantStock Option (Right to Buy) · Derivative 16,278 $0.00 Strike: $141.79 $0.00
Disclosure

SEC source: 0000950170-24-103643 · ownership.xml · derivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,278

Underlying: Common Stock · 16,278 shares

Expires 2034-09-03

F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on September 3, 2025, September 3, 2026, and September 3, 2027.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 00:41 UTC REPLIGEN CORP RGEN · Entity 486 GrantCommon Stock 17,631 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-103643 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,417

F1 · shares: Mr. Loeillot was awarded 17,631 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
February 27, 2024 Filed Mar 1, 2024 00:07 UTC REPLIGEN CORP RGEN · Entity 486 GrantStock Option (Right to Buy) · Derivative 2,860 $0.00 Strike: $192.71 $0.00
Disclosure

SEC source: 0000950170-24-023416 · ownership.xml · derivative · entry 2

Loeillot Olivier · CIK 0001995525 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,860

Underlying: Common Stock · 2,860 shares

Expires 2034-02-27

F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 27, 2025, February 27, 2026 and February 27, 2027.

Read SEC document
February 27, 2024 Filed Mar 1, 2024 00:07 UTC REPLIGEN CORP RGEN · Entity 486 GrantCommon Stock 2,880 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-023416 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,786

F1 · shares: Mr. Loeillot was awarded 2,880 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
October 02, 2023 Filed Oct 4, 2023 00:44 UTC REPLIGEN CORP RGEN · Entity 486 GrantStock Option (Right to Buy) · Derivative 24,236 $0.00 Strike: $154.96 $0.00
Disclosure

SEC source: 0000950170-23-051753 · ownership.xml · derivative · entry 2

Loeillot Olivier · CIK 0001995525 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,236

Underlying: Common Stock · 24,236 shares

Expires 2033-10-02

F2 · derivative.exercise_date: The shares vest in equal annual installments over a five-year period with each such vesting date occurring on the anniversary of the grant date.

Read SEC document
October 02, 2023 Filed Oct 4, 2023 00:44 UTC REPLIGEN CORP RGEN · Entity 486 GrantCommon Stock 12,906 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-051753 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,906

F1 · shares: Mr. Loeillot was awarded 12,906 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal installments over a five-year period with each such vesting date occurring on the anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.